Other Science

Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery

Retrieved on: 
Tuesday, April 9, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Astellas Pharma, Partnership, Plug and play, Patient, Therapy, Engineering, Inc., Pharmaceutical industry

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.

Key Points: 
  • Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients.
  • This agreement will leverage Invenra’s cutting-edge B-Body® bispecific antibody platform to support Astellas’ focused research and development initiatives.
  • Under the agreement, Astellas will have access to Invenra’s B-Body technology, marking a thoughtful step toward advancing their bispecific therapeutic research.
  • At the conclusion of the research, Astellas will have the option to negotiate future licenses.

Bayer’s Consumer Health Division Announces Changes to North America Leadership Team

Retrieved on: 
Tuesday, April 9, 2024
Other Communications, Other Health, Marketing, Communications, General Health, Other Natural Resources, Fitness & Nutrition, Agriculture, Natural Resources, Science, Vitamins, Supplements, Other Science, Health, Research, Medical Supplies, Growth, Philosophy, Business administration, BBDO, Diversity, University, Equity, Walmart, Bayer, Love, P&G, Aspirin, BBA, CMO, Tenneco, Multimedia, Loratadine, Advance Auto Parts, Avivi

Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America.

Key Points: 
  • Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America.
  • She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer.
  • View the full release here: https://www.businesswire.com/news/home/20240409885941/en/
    “I’m pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for none,‘” said Tomasi.
  • “I’m honored to take this leadership role with Bayer, a world leading company with a meaningful mission,” said Avivi.

ValGenesis Announces Contrader as New Implementation Partner for Italy

Retrieved on: 
Tuesday, April 9, 2024
Software, Professional Services, Business, Data Management, Start-Up, Apps, Applications, Technology, Science, Engineering, Consulting, Manufacturing, Other Science, Partner, Partnership, GMP, Multimedia, ICT, Cryptocurrency

ValGenesis and Contrader offer innovative, end-to-end digital solutions that help life sciences companies meet stringent regulatory requirements on their Industry 4.0 journey.

Key Points: 
  • ValGenesis and Contrader offer innovative, end-to-end digital solutions that help life sciences companies meet stringent regulatory requirements on their Industry 4.0 journey.
  • Contrader will implement and manage ValGenesis’ digital validation tools, including the industry-leading ValGenesis VLMS and VLMS Express , a simplified cloud-based digital validation solution for startups and midsized companies.
  • “Contrader is a key technology enabler and a reliable partner for the entire R&D platform.
  • Combining Contrader’s expertise with ValGenesis' cutting-edge offerings positions us well to navigate and overcome the complexities of digital transformation.

Cryogenic Processors Prepares to Open Premier Freeze Drying and Packaging Facility in Paducah, Kentucky

Retrieved on: 
Tuesday, April 9, 2024
Cosmetics, Chemicals, Plastics, Retail, Manufacturing, Supply Chain Management, Transport, Other Manufacturing, Science, Machinery, Logistics, Food, Beverage, Packaging, Other Science, Engineering, Research, Ice cream, Pelletizing, Freezing, Multimedia, Freeze-drying, Industrial gas

Cryogenic Processors, a trailblazer in the cryogenic freezing industry, is preparing to open a new, cutting-edge 115,000-square-foot cryogenic freezing and freeze drying facility in Paducah, Kentucky, in the fourth quarter of this year.

Key Points: 
  • Cryogenic Processors, a trailblazer in the cryogenic freezing industry, is preparing to open a new, cutting-edge 115,000-square-foot cryogenic freezing and freeze drying facility in Paducah, Kentucky, in the fourth quarter of this year.
  • View the full release here: https://www.businesswire.com/news/home/20240409729490/en/
    By providing a one-stop solution for cryogenic freezing, freeze drying and packaging, Cryogenic Processors is well-positioned to serve the needs of companies exploring flash freezing food, functional bacteria, flavorings, protein isolates, cosmetics and more.
  • The upcoming facility is not just an expansion of production capacity; it represents Cryogenic Processors' commitment to innovation, quality and customer service.
  • By providing a one-stop solution for cryogenic freezing, freeze drying and packaging, Cryogenic Processors is well-positioned to serve the needs of companies exploring flash freezing food, functional bacteria, flavorings, protein isolates, cosmetics and more.

Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Tuesday, April 9, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Metro Toronto Convention Centre, Conference, Q&A

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
  • Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, April 16, from 10:30 to 11:00 AM Eastern Time.
  • A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found here .

IGC Pharma Adds Advisor in Artificial Intelligence

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Other Technology, Research, Artificial Intelligence, Science, Clinical Trials, Diagnosis, Agitation, Biomedicine, Mathematics, Universidad, Algorithm, Biomedical engineering, Paris Dauphine University, Risk, Patient, Artificial intelligence, AI, University, Deep learning, Universidad de los Andes, Computer vision, IGC, GxP, Dementia, Medical device

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.
  • This will help IGC Pharma identify individuals who are most likely to respond to treatment and accelerate the delivery of treatments to patients.
  • Pablo Arbeláez is a distinguished researcher with over 20 years of experience in Computer Vision and Artificial Intelligence.
  • Ram Mukunda, CEO of IGC Pharma, stated, "We welcome Dr. Pablo Arbelaez to our team of Senior Advisors.

Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com’s Supplier Pre-assessment Program

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Research, Software, Genetics, Health Technology, Science, Data Management, Clinical Trials, Medicine, SVP, Collection, Category, Sanguine, Drug discovery

VERIF.i helps Scientist.com marketplace suppliers demonstrate internal processes and adherence to best practices to both existing and potential new clients.

Key Points: 
  • VERIF.i helps Scientist.com marketplace suppliers demonstrate internal processes and adherence to best practices to both existing and potential new clients.
  • “Through direct-to-donor engagement, Sanguine continues to amass one of the industry’s largest collections of ethically procured collections that includes extensive data about the biospecimens,” stated Sanguine CEO Brian Neman.
  • Their research products and services facilitate advanced therapy development programs from discovery to manufacturing.
  • “VERIF.i was developed to create a standardized process that helps researchers and sample providers ensure that the samples used in research meet their expected quality and ethical standards.”
    For more information on VERIF.i, visit https://www.scientist.com/verifi/

Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, B cell, Immunity, Cell, Patient, City, Tumor microenvironment, Cancer, AACR, Chemokine, Clinical trial, Immune system, Virus, Potyvirus, Poster, Vaccine

The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.

Key Points: 
  • The poster, titled “Deciphering anticancer mechanisms of oncolytic virus-loaded stem cells,” will be presented on April 9, 2024, during the Chemotherapy, Radiation, and Vaccine Mediated Immunity session.
  • “Calidi’s novel approach to treating cancer has always centered around the stem cell as a means of protecting, delivering, and potentiating our tumor-killing virotherapeutic payloads.
  • In the studies presented at AACR, scientists at Calidi Biotherapeutics and City of Hope researched the stem cells secretome transcriptomic of CLD-101 and CLD-201.
  • This poster will be posted to the “Scientific Publications” section of the Calidi Biotherapeutics website following the conclusion of the conference.

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

Retrieved on: 
Tuesday, April 9, 2024
Research, Clinical Trials, Biometrics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Cancer, Doctor, MSI-H, Metastasis, Communication, Immunotherapy, Colorectal cancer, Patient, MSI, STC, Team, Doctor of Philosophy, Master of Science, MSS, Neoplasm, Vaccine

This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.

Key Points: 
  • This communication confirms the ability of Brenus’ next gen immunotherapy, STC-1010, to fight against resistant colorectal tumors with excellent tolerability.
  • Additionally, multi-omics analysis of STC-1010 batches confirmed consistent quality and batch-to-batch reproducibility, through standardized and scalable production.
  • STC-1010 was tested in several models extrapolating human conditions (ex-vivo; in-ovo,) using PBMCs from different donors.
  • Results showed a significant immune response activation coupled with a massive and robust tumor killing that has been consistent with our 3 latest STC1010 batches manufactured.

Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act

Retrieved on: 
Tuesday, April 9, 2024
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Singapore International Arbitration Centre, TSX, Food, OTCQX

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the "Court") for an Initial Order under the Companies' Creditors Arrangement Act (the "CCAA").

Key Points: 
  • Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the "Court") for an Initial Order under the Companies' Creditors Arrangement Act (the "CCAA").
  • The application seeks an order that would, amongst other things, stay any action by Nuance Pharma to enforce the previously announced confidential ruling from the Singapore International Arbitration Centre requiring Antibe to pay approximately US$24 million to Nuance and would also enable the Company to continue engaging with the U.S. Food and Drug Administration with respect to the previously announced hold on the Company’s planned Phase II trial.
  • In addition, the Company announced that Amal Khouri and Jennifer McNealey have resigned from its Board of Directors effective April 8, 2024.
  • The Company thanks both Ms. Khouri and Ms. McNealey for their valuable contributions and wishes them well in their future endeavors.